WASHINGTON — The Trump administration published a final rule aimed at lowering Medicare prices for drugs administered in doctor offices. It applies to only four companies.
The Global Benchmark for Efficient Drug Pricing, or GLOBE, is one of two mandatory pilot programs that are part of President Trump’s plan to get drugmakers to lower prices in Medicare to levels charged in other rich countries, a policy generally referred to as most-favored nation pricing. The other pilot, called GUARD, is still in the proposed stage.
STAT Plus: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
The pilots are tied to Trump’s separate voluntary deals with drugmakers to offer MFN prices to drugs for Medicaid recipients. The companies that struck those deals are exempt from the GLOBE pilot, according to the model’s final rule.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.